Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
ACS Appl Mater Interfaces
; 15(30): 35895-35905, 2023 Aug 02.
Article
in En
| MEDLINE
| ID: mdl-37466148
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nanoparticles
/
COVID-19
Limits:
Animals
/
Humans
Language:
En
Journal:
ACS Appl Mater Interfaces
Journal subject:
BIOTECNOLOGIA
/
ENGENHARIA BIOMEDICA
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
Estados Unidos